Crosstalk between cystine and glutathione is critical for the regulation of amino acid signaling pathways and ferroptosis
1991 (landmark Italian trial): A double-blind, placebo-controlled trial involving 130 patients with Alzheimer's disease demonstrated that one year of ALCAR treatment resulted in a slower rate of deterioration compared to placebo across 13 of 14 outcome measures, including significant improvements in the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention [5][17]
Virtual compound libraries in computer-assisted drug discovery
Understanding these differences is crucial in deciding which treatment is right for you
Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88
Higher doses increase peptide consumption and cost without guaranteed proportional benefit increases